Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases

BMC Biochemistry

Volumn 4, Issue , 2003, Pages 1-15

  Wang, Qingcai ^a   Shaltiel, Shmuel ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GUANIDINE; MUTANT PROTEIN; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; ALANINE; ARGININE; GLUTAMIC ACID; SERINE PROTEINASE INHIBITOR;

AMINO ACID SEQUENCE; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STABILITY; ENZYME SUBSTRATE COMPLEX; FIBROSARCOMA; INHIBITION KINETICS; LATENT PERIOD; PROTEIN DENATURATION; PROTEIN FOLDING; REACTION TIME; WILD TYPE; CHEMISTRY; GENETICS; HUMAN; KINETICS; METABOLISM; MOLECULAR GENETICS; MUTATION; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT; TUMOR CELL LINE;

UNIDENTIFIED BACULOVIRUS;

ALANINE; AMINO ACID SEQUENCE; ARGININE; CELL LINE, TUMOR; FIBRINOLYSIN; GLUTAMIC ACID; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; THROMBIN;

EID: 0942295654     PISSN: 14712091     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2091-4-5     Document Type: Article

References (30)

1. Ny T, Sawdey M, Lawrence D, Millan JL and Loskutoff DJ: Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor Proc Natl Acad Sci USA 1986, 83:6776-80.
2. Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij CL, van Zonneveld AJ and van Mourik JA: Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family EMBO J 1986, 5:2539-44.
3. Bernd R. Binder Günter Christ, Florian Gruber, Nelly Grubic, Peter Hufnagl, Michael Krebs, Judit Mihaly and Gerald W. Prager: Plasminogen Activator Inhibitor 1: Physiological and Pathophysiological Roles News Physiol Sci 2002, 17:56-61.
4. Loskutoff DJ and Schleef RR: Plasminogen activators and their inhibitors Methods Enzymol 1988, 163:293-302.
5. Andreasen PA Egelund R, Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis Cell Mol Life Sci 2000, 57:25-40.
6. Kohler HP Grant PJ: Plasminogen-activator inhibitor type 1 and coronary artery disease N Engl J Med 2000, 342:1792-1801.
7. Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG and Marotti KR: Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene Nature 1990, 346:74-6 issn: 0028-0836.
8. Nordt TK Peter K, Ruef J, Kubler W, Bode C: Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease Thromb Haemost 1999, 82 Suppl 1:14-18.
9. Carmeliet P, Kieckens L, Schoonjans L, Ream B, van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D and Mulligan RC: Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization J Clin Invest 1993, 92:2746-2755.
10. Huber R and Carrell RW: Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins Biochemistry 1989, 28:8951-8966.
11. Sharp AM, Stein PE, Pannu NS, Carrell RW, Berkenpas MB, Ginsburg D, Lawrence DA and Read RJ: The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion Structure Fold Des 1999, 7:111-118.
12. Stout TJ, Graham H, Buckley DI and Matthews DJ: Structures of active and latent PAI-1: a possible stabilizing role for chloride ions Biochemistry 2000, 39:8460-8469.
13. Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD and Goldsmith EJ: Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992, 355:270-273.
14. Sherman PM, Lawrence DA, Yang AY, Vandenberg ET, Paielli D, Olson ST, Shore JD and Ginsburg D: Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center J Biol Chem 1992, 267:7588-7595.
15. Sherman PM, Lawrence DA, Verhamme IM, Paielli D, Shore JD and Ginsburg D: Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity. J Biol Chem 1995, 270:9301-9306.
16. Keijer J, Linders M, van Zonneveld AJ, Ehrlich HJ, de Boer JP and Pannekoek H: The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance Blood 1991, 78:401-409.
17. Madison EL, Goldsmith EJ, Gerard RD, Gething MJ, Sambrook JF and Bassel-Duby RS: Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1 Proc Natl Acad Sci U S A 1990, 87:3530-3533.
18. Madison EL, Goldsmith EJ, Gething MJ, Sambrook JF and Gerard RD: Restoration of serine protease-inhibitor interaction by protein engineering J-Biol-Chem 1990, 265:21423-6.
19. Madison EL, Goldsmith EJ, Gerard RD, Gething MJ and Sambrook JF: Serpin-resistant mutants of human tissue-type plasminogen activator. Nature 1989, 339:721-724.
20. Lawrence DL, Strandberg L, Grundstrom T and Ny T: Purification of active human plasminogen activator inhibitor-1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. Eur J Biochem 1989, 186:523-533.
21. Shore JD, Day DE, Francis-Chmura AM, Verhamme I, Kvassman J, Lawrence DA and Ginsburg D: A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism J Biol Chem 1995, 270:5395-5398.
22. Berkenpas MB Lawrence DA, Ginsburg D: Molecular evolution of plasminogen activator inhibitor-1 functional stability EMBO J 1995, 14:2969-2977.
23. A. Allart Stoopa Eric Elderinga, Timothy R. Daffornb, Randy J. Readb and Hans Pannekoek: Different Structural Requirements for Plasminogen Activator Inhibitor 1 (PAI-1) during Latency Transition and Proteinase Inhibition as Evidenced by Phage-displayed Hypermutated PAI-1 Libraries J Mol Biol 2001, 305:773-783.
24. Matsumura M, Becktel WJ and Matthews BW: Hydrophobic stabilization in T4 lysozyme determined directly by multiple substitutions of Ile 3 Nature 1988, 334:406-410.
25. Plotnick MI, Schechter NM, Wang ZM, Liu X and Rubin H: Role of the P6-P3′ region of the serpin reactive loop in the formation and breakdown of the inhibitory complex Biochemistry 1997, 36:14601-14608.
26. Rezaie AR: Elucidation of the structural basis for the slow reactivity of thrombin with plasminogen activator inhibitor-1. Biochemistry 1998, 37:13138-13142.
27. Lawrence DA, Strandberg L, Ericson J and Ny T: Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants J Biol Chem 1990, 265:20293-20301.
28. Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, Dano K, Lebo RV and Gelehrter TD: cDNA cloning of human plasminogen activator-inhibitor from endothelial cells J Clin Invest 1986, 78:1673-80.
29. Ausubel FM, R, Brent RE, Kingston DD, Moore JG, Seidman JA, Smith and and Struhl. K: Current protocols in molecular biology John Wiley & Sons, Inc; 1996.
30. Kjoller L, Martensen PM, Sottrup Jensen L, Justesen J, Rodenburg KW and Andreasen PA: Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1. Eur J Biochem 1996, 241:38-46.